Guggenheim raised the firm’s price target on Axsome Therapeutics (AXSM) to $195 from $135 and keeps a Buy rating on the shares after updating the firm’s model following Axsome’s Q4 report.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics Sees Robust Growth and Strategic Progress
- Axsome Therapeutics Inc. Earnings Report: Is it a Beat?
- Axsome Therapeutics’ Earnings Call: Growth Amid Challenges
- Axsome Therapeutics: Strong Performance and Promising Pipeline Justify Buy Rating
- Axsome Therapeutics reports Q4 EPS ($1.54), consensus ($1.00)